Victory Capital Management Inc Akero Therapeutics, Inc. Transaction History

Victory Capital Management Inc

  • $99 Billion
  • Q3 2024

A detailed history of Victory Capital Management Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 7,370 shares of AKRO stock, worth $229,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,370
Holding current value
$229,944
% of portfolio
0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024
BUY
$21.45 - $29.34 $158,086 - $216,235
7,370 New
7,370 $211,000
Q4 2023

Feb 05, 2024
SELL
$11.38 - $50.33 $2.04 Million - $9.04 Million
-179,572 Reduced 92.83%
13,880 $324,000
Q3 2023

Nov 06, 2023
SELL
$41.19 - $52.25 $4.29 Million - $5.44 Million
-104,120 Reduced 34.99%
193,452 $9.78 Million
Q2 2023

Jul 27, 2023
BUY
$36.89 - $56.88 $3.47 Million - $5.35 Million
93,990 Added 46.17%
297,572 $13.9 Million
Q1 2023

May 02, 2023
BUY
$37.27 - $50.24 $7.44 Million - $10 Million
199,495 Added 4881.21%
203,582 $7.79 Million
Q4 2022

Feb 10, 2023
BUY
$33.44 - $54.8 $1,237 - $2,027
37 Added 0.91%
4,087 $223,000
Q4 2022

Feb 09, 2023
SELL
$33.44 - $54.8 $507,084 - $830,987
-15,164 Reduced 78.92%
4,050 $221,000
Q3 2022

Nov 02, 2022
SELL
$10.15 - $34.05 $7,125 - $23,903
-702 Reduced 3.52%
19,214 $654,000
Q2 2022

Aug 01, 2022
SELL
$8.0 - $15.01 $80 - $150
-10 Reduced 0.05%
19,916 $188,000
Q1 2022

May 04, 2022
BUY
$12.97 - $22.26 $9,299 - $15,960
717 Added 3.73%
19,926 $209,000
Q4 2021

Feb 07, 2022
SELL
$19.87 - $26.24 $54,900 - $72,501
-2,763 Reduced 12.58%
19,209 $406,000
Q3 2021

Nov 02, 2021
BUY
$18.65 - $25.46 $578 - $789
31 Added 0.14%
21,972 $491,000
Q2 2021

Aug 03, 2021
SELL
$24.81 - $32.35 $25,331 - $33,029
-1,021 Reduced 4.45%
21,941 $544,000
Q1 2021

May 04, 2021
SELL
$24.04 - $34.19 $25,434 - $36,173
-1,058 Reduced 4.4%
22,962 $666,000
Q4 2020

Feb 01, 2021
SELL
$25.12 - $29.89 $25,672 - $30,547
-1,022 Reduced 4.08%
24,020 $620,000
Q3 2020

Nov 09, 2020
SELL
$30.79 - $39.92 $266,826 - $345,946
-8,666 Reduced 25.71%
25,042 $771,000
Q2 2020

Aug 07, 2020
SELL
$19.25 - $26.76 $4,543 - $6,315
-236 Reduced 0.7%
33,708 $840,000
Q1 2020

May 04, 2020
BUY
$12.8 - $27.05 $413,900 - $874,688
32,336 Added 2010.95%
33,944 $720,000
Q4 2019

Feb 06, 2020
SELL
$17.37 - $27.27 $565,845 - $888,347
-32,576 Reduced 95.3%
1,608 $36,000
Q4 2019

Feb 04, 2020
BUY
$17.37 - $27.27 $548,110 - $860,504
31,555 Added 1200.27%
34,184 $844,000
Q3 2019

Nov 12, 2019
BUY
$16.89 - $29.88 $17,244 - $30,507
1,021 Added 63.5%
2,629 $60,000
Q2 2019

Aug 15, 2019
BUY
$18.08 - $19.83 $29,072 - $31,886
1,608 New
1,608 $31,000

Others Institutions Holding AKRO

# of Institutions
190
Shares Held
73.8M
Call Options Held
241K
Put Options Held
647K
View Full List

About Akero Therapeutics, Inc.

AKRO Quotes by TradingView
  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.45B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email